Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598934 (
tumor growth
)
58,965
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Nuclear factor I/B
(
NFIB
) is a widely studied transcription factor that participates in tumor progression; nevertheless, studies on
NFIB
in colorectal cancer (CRC) are limited. In our study, Western blot and RT-PCR analyses showed that
NFIB
was overexpressed in CRC tissues and cell lines, which was consistent with our bioinformatic analysis results. Furthermore,
NFIB
expression was closely related to the TNM stage of CRC.
NFIB
promoted cell proliferation and migration and inhibited cell apoptosis in vitro. Meanwhile, we discovered that
NFIB
accelerated xenograft
tumor growth
in vivo. In addition,
NFIB
weakened the sensitivity of CRC cells to 5-fluorouracil (5-FU).
NFIB
induced epithelial-mesenchymal transition (EMT) by upregulating snail expression, which was accompanied by decreased E-cadherin and Zo-1 expression and increasedd Vimentin expression. Because the Akt pathway plays an important role in CRC progression, we examined whether there was a correlation between
NFIB
and the Akt pathway in cell proliferation and migration. Our results showed that
NFIB
promoted cell proliferation and increased 5-FU resistance by activating the Akt pathway. In summary, our findings suggested that
NFIB
induced EMT of CRC cells via upregulating snail expression and promoted cell proliferation and 5-FU resistance by activating the Akt pathway.
...
PMID:Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial-mesenchymal transition and 5-fluorouracil resistance. 3032 Sep 39